|
UBE4B expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.68949999546086E-08 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.04659999958734E-07 |
| Normal-vs-Stage2 |
2.341700E-03 |
| Normal-vs-Stage3 |
1.03370000004155E-07 |
| Normal-vs-Stage4 |
1.52194999999411E-05 |
| Stage1-vs-Stage2 |
4.499200E-01 |
| Stage1-vs-Stage3 |
6.752000E-02 |
| Stage1-vs-Stage4 |
3.191200E-01 |
| Stage2-vs-Stage3 |
5.501600E-02 |
| Stage2-vs-Stage4 |
1.254370E-01 |
| Stage3-vs-Stage4 |
6.925600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.31360000549452E-08 |
| Normal-vs-AfricanAmerican |
2.798000E-02 |
| Normal-vs-Asian |
5.415500E-03 |
| Caucasian-vs-AfricanAmerican |
2.103800E-01 |
| Caucasian-vs-Asian |
6.804300E-02 |
| AfricanAmerican-vs-Asian |
9.193000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.68969999999802E-05 |
| Normal-vs-Female |
1.14560000374908E-08 |
| Male-vs-Female |
2.964000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.20549999999653E-05 |
| Normal-vs-Age(41-60Yrs) |
6.30459999984012E-07 |
| Normal-vs-Age(61-80Yrs) |
2.37910000000507E-06 |
| Normal-vs-Age(81-100Yrs) |
1.66194999999814E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.783600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.563190E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
3.485500E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.099200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.865800E-02 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.448100E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.963800E-01 |
| Classical-VS-Follicular |
6.978600E-01 |
| Classical-VS-Other |
7.292800E-01 |
| Classical-VS-Normal |
4.01480000000731E-05 |
| Tall-VS-Follicular |
5.853600E-01 |
| Tall-VS-Other |
4.478000E-01 |
| Tall-VS-Normal |
8.04130000000569E-05 |
| Follicular-VS-Other |
6.519200E-01 |
| Follicular-VS-Normal |
2.25259999999672E-05 |
| Other-VS-Normal |
1.629250E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
7.63149999971624E-07 |
| Normal-vs-N1 |
1.85550000031398E-07 |
| N0-vs-N1 |
8.450100E-02 |
|
|
